Differential responses to JNJ-37822681, a specific and fast dissociating dopamine D2 receptor antagonist, in cynomolgus monkey and Sprague-Dawley rat general toxicology studies: Clinical observations, prolactin levels, mammary histopathology findings and toxicokinetics

Journal of Applied Toxicology

Volumn 34, Issue 9, 2014, Pages 974-992

  de Waal, Eric J ^a   Desmidt, Maria ^a   Korte, Sven ^b   Niehoff, Marc ^b   Chase, Kevan ^c   Arrowsmith, Wayne ^c   Lampo, Ann ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b Department of Veterinary Services and Colony Management   (Germany)

^c Huntingdon Research Centre   (United Kingdom)

Author keywords

Antipsychotic; EPS; Extrapyramidal symptoms; JNJ 37822681; Monkey; Prolactin; Rat

Indexed keywords

DOPAMINE 2 RECEPTOR BLOCKING AGENT; JNJ 37822681; PROLACTIN; UNCLASSIFIED DRUG; N-(1-(3,4-DIFLUOROBENZYL)PIPERIDIN-4-YL)-6-(TRIFLUOROMETHYL)PYRIDAZIN-3-AMINE; NEUROLEPTIC AGENT; PIPERIDINE DERIVATIVE; PYRIDAZINE DERIVATIVE;

ABNORMAL POSTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST DISEASE; CLINICAL OBSERVATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; EXPOSURE; EXTRAPYRAMIDAL SYMPTOM; EYE MOVEMENT DISORDER; FEMALE; HALLUCINATION; HISTOPATHOLOGY; MACACA FASCICULARIS; MALE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RAT; REPEATED DRUG DOSE; SCHIZOPHRENIA; SPECIES DIFFERENCE; SPRAGUE DAWLEY RAT; TOXICITY TESTING; TOXICOKINETICS; ANIMAL; DOSE RESPONSE; HUMAN; METABOLISM; PATHOLOGY; UDDER;

MACACA FASCICULARIS; RATTUS;

ANIMALS; ANTIPSYCHOTIC AGENTS; DOPAMINE D2 RECEPTOR ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MACACA FASCICULARIS; MALE; MAMMARY GLANDS, ANIMAL; PIPERIDINES; PROLACTIN; PYRIDAZINES; RATS; RATS, SPRAGUE-DAWLEY; SCHIZOPHRENIA; TOXICITY TESTS;

EID: 84904972873     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.2916     Document Type: Article

References (52)

1. Andreasen NC. 2000. Schizophrenia: the fundamental questions. Brain Res. Rev. 31: 106-112.
2. 2 receptor antagonist JNJ-37822681 in patients with acute schizophrenia? Eur. Neuropsychopharmacol., available on line 18 September 2012, http://ac.els-cdn.com/S0924977X12002507/dx.doi.org/10.1016/j.euroneuro.2012.08.017
3. 2 receptor mechanisms contribute to age-related cognitive decline: the effects of quinpirole on memory and motor performance in monkeys. J. Neurosci. 15(5): 3429-3439.
4. 1A antipsychotics on catalepsy-associated behavior in cynomolgus monkeys. Behav. Brain Res. 203: 288-295.
5. Ballanger B, Strafella AP, van Eimeren T, Zurowski M, Rusjan PM, Houle S, Fox SH. 2010. Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch. Neurol. 67(4): 416-421.
6. Ben-Jonathan N, LaPensee CR, LaPensee EW. 2008. What can we learn from rodents about prolactin in humans? Endocr. Rev. 29: 1-41.
7. Bernichtein S, Touraine P, Goffin V. 2010. New concepts in prolactin biology. J. Endocrinol. 206: 1-11.
8. Boyda HN, Tse L, Procyshyn RM, Honer WG, Barr AM. 2010. Preclinical modesl of antipsychotic drug-induced metabolic side effects. Trends Pharmacol. Sci. 31: 484-497.
9. Casey DE. 1993. Serotonergic and dopaminergic aspects of neuroleptic-induced extrapyramidal syndromes in nonhuman primates. Psychopharmacology (Berl) 112: S55-S59.
10. Casey DE. 1996. Behavioral effects of sertindole, risperidone, clozapine and haloperidol in Cebus monkeys. Psychopharmacology (Berl) 12: 134-140.
11. Cline JM. 2007. Assessing the mammary gland of nonhuman primates: effects of endogenous hormones and exogenous hormonal agents and growth factors. Birth Defects Res. (Part B) 80: 126-146.
12. Cline JM, Wood CE. 2008. The mammary glands of macaques. Toxicol. Pathol. 36: 130S-141S.
13. Dickson RA, Glazer WM. 1999. Neuroleptic-induced hyperprolactinemia. Schizophr. Res. 35: S75-S86.
14. Fénelon G, Mahieux F, Huon R, Ziégler M. 2000. Hallucinations in Parkinson's disease. Prevalence, phenomenology and risk factors. Brain 123(4): 733-745.
15. Fukuoka T, Nakano M, Kohda A, Okuno Y, Matsuo M. 1997. The common marmoset (Callithrix jacchus) as a model for neuroleptic-induced acute dystonia. Pharmacol. Biochem. Behav. 58(4): 947-953.
16. Goldstein JM, Snyder DH. 1995. Effects of seroquel (R) and other atypical antipsychotics in primate models of EPS. Biol. Psychiatry 37(9): 646-647.
17. Goodnick PJ, Rodriguez L, Santana O. 2002. Antipsychotics: impact on prolactin levels. Exp. Opin. Pharmacother. 3(10): 1381-1391.
18. Gründer G, Hippius H, Carlsson A. 2009. The 'atypicality' of antipsychotics: a concept re-examined and re-defined. Nat. Rev. Drug Discov. 8: 197-202.
19. Hargreaves A, Harleman J. 2011. Preclinical risk assessment of drug-induced hypo- and hyperprolactinemia. J. Appl. Toxicol. 31: 599-607.
20. Harleman JH, Hargreaves A, Andersson H, Kirk S. 2012. A review of the incidence and coincidence of uterine and mammary tumors in Wistar and Sprague-Dawley rats based on the RITA database and the role of prolactin. Toxicol. Pathol. 40: 926-930.
21. Harvey PW. 2005. Human relevance of rodent prolactin-induced non-genotoxic mammary carcinogenesis: prolactin involvement in human breast cancer and significance for toxicologic risk assessments. J. Appl. Toxicol. 25: 179-183.
22. Harvey PW. 2011. Prolactin-induced mammary tumorigenesis is not a rodent-specific response. Toxicol. Pathol. 39: 1020-1022.
23. Harvey PW. 2012. Hypothesis. Prolactin is tumorigenic to human breast: dispelling the myth that prolactin-induced mammary tumors are rodent-specific. J. Appl. Toxicol. 32: 1-9.
24. Hoffman DC, Donovan H. 1995. Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability. Psychopharmacology (Berl) 120(2): 128-133.
25. ICH. 1998. ICH harmonized tripartite guideline. Duration of chronic toxicity testing in animals (rodent and non rodent toxicity testing). S4. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use.
26. ICH. 2009. ICH harmonized tripartite guideline. Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. M3(R2). International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use.
27. 2 receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol. Psychiatry 50: 873-883.
28. 2 receptor explain the action of atypical antipsychotics?: a new hypothesis. Am. J. Psychiatry 158: 360-369.
29. Kapur S, Langlois X, Vinken P, Megens AAHP, De Coster R, Andrews JS. 2002. The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. J. Pharmacol. Exp. Ther. 302(3): 1129-1134.
30. Kumar R, Palit G, Dhawan BN. 2003. Comparative behavioural effects of typical and atypical antipsychotic drugs in rhesus monkey. Eur. J. Pharmacol. 462: 133-138.
31. 2 antagonist for the treatment of schizophrenia. J. Pharmacol. Exp. Ther. 342: 91-105.
32. Liebman J, Neale R. 1980. Neuroleptic-induced acute dyskinesias in squirrel monkeys: correlation with propensity to cause extrapyramidal side effects. Psychopharmacology (Berl) 68: 25-29.
33. Manford M, Andermann F. 1998. Complex visual hallucinations. Clinical and neurobiological insights. Brain 121(10): 1819-1840.
34. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. 2005. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry 10: 79-104.
35. OECD. 1997. Principles of Good Laboratory Practice. Organization of Economic Co-operation and Development.
36. Peacock L, Gerlach J. 1999. New and old antipsychotics versus clozapine in a monkey model: adverse effects and antiamphetamine effects. Psychopharmacology (Berl) 144: 189-197.
37. Peveler RC, Branford D, Citrome L, Fitzgeral P, Harvey PW, Holt RIG, Howard L, Kohen D, Jones I, O'Keane V, Pariente CM, Pendlebury J, Smith SM, Yeomans D. 2008. Antipsychotics and hyperprolactinemia: clinical recommendations. J. Psychopharmacol. 22(2, Suppl.): 98-103.
38. Pierre JM. 2005. Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management. Drug Saf. 28(3): 191-208.
39. Porsolt RD, Jalfre M. 1981. Neuroleptic-induced acute dyskinesias in rhesus monkeys. Psychopharmacology (Berl) 75: 16-21.
40. Reddy VP, Petersson KJ, Suleiman AA, Vermeulen A, Proost JH, Friberg LE. 2012. Pharmacokinetic-pharmacodynamic modeling of severity levels of extrapyramidal side effects with Markov elements. CPT: Pharmacometrics Systems Pharmacol. 1, e1, doi: 10.1038/psp.2012.9, 1-9.
41. Rehm S, Stanislaus DJ, Wier PJ. 2007. Identification of drug-induced hyper- or hypoprolactinemia in the female rat based on general and reproductive toxicity study parameters. Birth Defects Res. (Part B) 80: 253-257.
42. Rourke C, Starr DR, Reavill C, Fenwick S, Deadman K, Jones DNC. 2006. Effects of the atypical antipsychotics olanzapine and risperidone on plasma prolactin levels in male rats: a comparison with clinical data. Psychopharmacology (Berl) 184: 107-114.
43. Rudel RA, Attfield KR, Schifano JN, Brody JG. 2007. Chemicals causing mammary tumors in animals signal new directions for epidemiology, chemicals testing, and risk assessment for breast cancer prevention. Cancer 109 (12 Suppl.): 2635-2636.
44. Russo IH, Russo J. 1996. Mammary gland neoplasia in long-term rodent studies. Environ. Health Perspect. 104(9): 938-967.
45. Sachdev PS, Brüne M. 2000. Animal models of acute drug-induced akathisia - a review. Neurosci. Biobehav. Rev. 24: 269-277.
46. 2 receptor antagonist in the treatment of acute exacerbation of schizophrenia. Eur. Neuropsychopharmacol. 22: 721-733.
47. 2 receptor in schizophrenia. Exp. Opin. Ther. Targets 10(4): 515-531.
48. Strange PG. 2008. Antipsychotic drug action: antagonism, inverse agonism or partial agonism. Trends Pharmacol. Sci. 29(6): 314-321.
49. 11] raclopride and positron emission tomography. J. Psychopharmacol. 26(8): 1128-1135.
50. 2 receptor antagonist JNJ-37822681. J. Psychopharmacol. 26(8): 1119-1127.
51. 2A antagonists on haloperidol-induced movement disorders in primates. Psychopharmacology (Berl) 200(3): 393-401.
52. Weiss B, Santelli S, Lusink G. 1977. Movement disorders induced in monkeys by chronic haloperidol treatment. Psychopharmacology (Berl) 53(3): 289-293.